David Shaw’s Lifecore Biomedical LFCR Stock Holding History

David Shaw’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q4	–	Sell	-12,000	Closed	-$146K	–	4578
2013 Q3	$146K	Hold	12,000	–	–	﹤0.01%	4151
2013 Q2	$159K	Buy	+12,000	New	+$166K	﹤0.01%	3803

Other funds holding LFCR

22NW LP Seattle, Washington $105M AUM 38.33% 1-Year Est. Return

Wynnefield Capital New York $145M AUM 14.57% 1-Year Est. Return

LPAM

Legion Partners Asset Management Los Angeles, California $40.6M AUM 156.55% 1-Year Est. Return

GRIM

Greenhaven Road Investment Management Greenwich, Connecticut $154M AUM 15.9% 1-Year Est. Return

325 Capital New York $419M AUM 75.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Grizzlyrock Capital Chicago, Illinois $143M AUM 6.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

David Shaw's LFCR Position: Q1 2026 in Review

David Shaw sold out of Lifecore Biomedical (LFCR) in Q1 2026, closing a stake of 37,428 shares — an estimated $306K sold.

David Shaw first reported a position in LFCR in Q3 2015 and held it in 26 quarters. The position peaked at $1.14M in Q2 2021. 105 funds tracked by Wall St. Rank hold LFCR as of Q1 2026.

David Shaw reported no remaining Lifecore Biomedical position as of Q1 2026 after selling out during the quarter.
David Shaw sold 37,428 Lifecore Biomedical shares in Q1 2026, an estimated $306K.
David Shaw first reported a position in Lifecore Biomedical in Q3 2015 and held it in 26 quarters.
David Shaw's Lifecore Biomedical position peaked at $1.14M in Q2 2021.
105 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.